Our Experts

Michael Singer has over three decades of leadership experience in operations, investments, and finance in the healthcare industry. Michael began his career as an academic political economist and then was an M&A and healthcare investment banker for over a decade in NY and San Francisco.

Thereafter, he was CFO of VC-backed Data Critical Corp, taking the company public before selling it to GE, an executive at Microsoft, and President of Revolution Health investments (founded by Steve Case). Michael has been a founding CEO and executive chairman of two neurological device companies navigating through 9 FDA clearances and tens of millions of dollars of DoD research contracts and venture financing. He has founded or been first investor in multiple companies, including Healthcare Innovation Catalysts, and has served on both public and private Boards. Michael holds a Ph.D. from the LSE.

Joseph (Joe) Biehl brings more than 35 years of executive leadership experience helping pharmaceutical, biotechnology, and medical device organizations operate, scale, and remain compliant in highly regulated environments. He has partnered with clients across North America, Europe, and Asia to solve complex operational, quality, and regulatory challenges, with a focus on enabling sustainable growth, improving performance, and reducing risk.

Joe has led global teams delivering GMP compliance, validation, engineering, regulatory affairs, pharmacovigilance, and medical information services to both emerging and established life sciences companies. He has helped clients remediate regulatory gaps, modernize quality systems, execute large-scale expansions, integrate acquisitions, and maintain uninterrupted operations during periods of rapid growth and organizational change. His work has supported successful inspections, product launches, technology transfers, and long-term operational resilience. Joe holds a BS in Mechanical Engineering from Drexel University and a graduate certificate in pharmaceutical and medical device law and compliance from Seton Hall Law School.

Ben Eloff brings nearly 20 years of federal leadership in advancing medical innovation and regulatory science. At FDA, he pioneered the first Bayesian device trial and co-authored the agency’s real-world evidence guidance. He led the launch of public-private initiatives including the Cardiac Safety Research Consortium and KidneyX.

He managed over $50 million in grants, contracts, and prizes to accelerate innovation. Ben held senior roles at FDA and HHS and earned his Ph.D. in Biomedical Engineering from Case Western Reserve University.

Thom Mezak is a business operations executive with deep experience across quality, regulatory, and clinical services in the life sciences. He leads operational design and delivery for complex consulting engagements from early strategy through postmarket support, with strengths in scalable project infrastructure, resourcing models, and statements of work. He has overseen global teams of 100+ experts and managed portfolios exceeding $2 million in monthly revenue. His background spans margin optimization, risk mitigation, and technical delivery across pharmaceutical, biotechnology, and medical device programs, supported by prior hands-on experience in analytical quality control and financial systems.

Brit Valdez-Nava has extensive experience managing FDA regulatory filings, developing drug and device quality management systems (QMS), and overseeing GMP operations. She previously managed cellular/gene therapy manufacturing quality operations and consulted for medical device companies. She holds a master’s degree in Regulatory Science from Johns Hopkins University.